Potential and progress in targeting less common markers: HER2, BRAF, KRAS, MET, TRK, and RET

Описание к видео Potential and progress in targeting less common markers: HER2, BRAF, KRAS, MET, TRK, and RET

In this presentation from the 22nd Annual Perspectives in Thoracic Oncology, Dr. Joshua Bauml discusses the potential of and progress in targeteing less common markers including HER2, BRAF, KRAS, MET, TRK, and RET.

Earn CME credit for a related activity at the following location:
http://elc.imedex.com/ELC/Specialty-S...

© 2017 Imedex, LLC.

Комментарии

Информация по комментариям в разработке